Background: The neurobiological basis of autism remains poorly understood. We hypothesized that endothelial antibodies may be associated with the pathophysiology of autism and may predict intellectual/social developmental abnormalities. Methods: Plasma levels of antiendothelial cell antibodies (AECAs) were measured by enzyme-linked immunosorbent assay in autistic children (n ¼ 55) and age-matched healthy controls (n ¼ 25). Results: The serum level of AECAs in children with autism {n ¼ 55, 306.4 ± 45.6 pg/mL [mean ± standard error of the mean (SEM)]} was higher (two-tailed Student t test: p ¼ 0.05) than that of healthy controls [n ¼ 25, 209.6 ± 24.6 pg/mL (mean ± SEM)]. Children with severe autism exhibited significantly higher AECAs than healthy controls (diagnoses of autistic children based on the Childhood Autism Rating Scale score, >40) [n ¼ 20, 369.6 ± 65.6 pg/mL (mean ± SEM)] ( p ¼ 0.03). Disease severity and the Childhood Autism Rating Scale score, which represent stereotyped patterns of behavior in children with autism, were positively correlated (r 2 ¼ 0.27, p ¼ 0.05). Conclusion: Elevated AECA serum levels may be implicated in the pathogenesis of autism. However, these data should be interpreted with caution until further investigations are performed using larger sample sizes to determine whether the increase in serum AECA levels is a mere consequence of autism or it plays a pathogenic role in the disease.
Introduction
Children with autism exhibit marked deficits in interpersonal social behaviors, abnormal language development, restricted interests, stereotypic/ritualistic behaviors that accompany a particular developmental course, and evidence of developmental delay within the first 3 years of life. Autoimmunity to the central nervous system may play a pathogenic role in autism spectrum disorder (ASD). 5e7 Recently, two lines of research have focused on biological factors in autism. First, excesses of neurotrophins and neuropeptides in infant sera have a predictive value in determining those children who later exhibit disruption of intellectual and or social development. 6 We have established that one of these factors, brain-derived neurotrophic factor, is elevated in children with autism. 8 Second, autoantibodies to several antigenic targets are present in the sera of some children with neurodevelopmental disorders. 9, 10 These facts have led us to search for biological markers that may allow earlier detection of autism. In this study, we determined the serum levels of antiendothelial cell antibodies (AECAs) in a group of wellConflicts of interest: The authors declare that there are no conflicts of interest related to the subject matter or materials discussed in this article.characterized children with autism and a healthy control group.
AECAs are observed in various autoimmune diseases, including systemic lupus erythematosus, scleroderma, mixed connective tissue diseases, hemolytic uremic syndrome, Sjogren's syndrome, rheumatoid arthritis, vasculitis, lupus nephritis, Kawasaki disease, and progressive systemic sclerosis. 11e15 However, serum levels of endothelial cells in patients with autism have never been reported. Thus, the aim of this study was to explore a possible role for AECAs in patients with ASD.
Methods

Participants
This caseecontrol study was conducted with 55 children with classic-onset autism. The autistic group consisted of 47 males and eight females. The children were recruited from the Autism Research and Treatment Center, Faculty of Medicine, King Saud University, Riyadh, Saudi Arabia. Their ages ranged between 3 years and 12 years (mean ± SD ¼ 7.98 ± 2.59 years). The patients fulfilled the criteria for the diagnosis of autism according to the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders. 1 We excluded patients with associated neurological diseases (such as cerebral palsy and tuberous sclerosis) or associated metabolic disorders (e.g., phenylketonuria) because the association of these comorbidities with autism may influence AECA levels. Patients were not receiving any medications.
The control group consisted of 25 age-and sex-matched healthy children (21 males and 4 females). The children's ages ranged between 4 years and 12 years (mean ± SD ¼ 8.79 ± 2.89 years). The children were the healthy older siblings of healthy children who attend the Well Baby Clinic, King Khalid University Hospital, Faculty of Medicine, King Saud University, for routine follow-up of their growth parameters. In addition, informed written consent for participation in the study was given by the parents or legal guardians of the participants.
Study measurements
Clinical evaluation of autistic patients was based on clinical histories provided by caregivers, clinical examinations, and neuropsychiatric assessments. In addition, the degree of autism severity was assessed using the Childhood Autism Rating Scale (CARS), 16 which rates the child on a scale from one to four in each of 15 areas (relating to people; emotional response; imitation; body use; object use; listening response; fear or nervousness; verbal and nonverbal communication; activity level; level and consistency of intellectual response; adaptation to change; visual response; taste, smell, and touch response; and general impressions). According to the scale, children who score 30e36 have mild to moderate autism (n ¼ 35), whereas those with scores ranging between 37 points and 60 points have severe autism (n ¼ 20).
Blood samples
After overnight fasting, blood samples (3 mL) were collected from participants of both groups in plain test tubes. Blood samples were allowed to clot and were then centrifuged at 3000 rpm to collect serum samples, which were stored in a freezer at À80 C until they were analytically assayed. A detailed description of the procedure has been provided in our previous reports. 3, 17 To increase accuracy, all samples were analyzed twice in two independent experiments to assess interassay variations and ensure the reproducibility of the observed results ( p > 0.05).
Assessment of serum AECAs
Levels of AECAs were measured using a commercially available sandwich enzyme immunoassay (enzyme-linked immunosorbent assay) kit from Cusabio Biotech Co., Ltd (Wuhan, China). No significant cross-reactivity or interference was observed.
Statistical analysis
The results were analyzed using the commercially available software package Statview (Abacus Concepts, Inc., Berkley, CA, USA). The data are presented as the mean ± standard error of the mean (SEM). The ManneWhitney U test was used for comparisons between data. Spearman's rank correlation coefficient "r" was used to determine the relationship between variables. For all tests, p < 0.05 was considered significant. The receiver operating characteristic curve is a plot of sensitivity versus 1-specificity at different cutoff values of the studied variable. The uppermost left point represents the best cutoff value (based on the highest sensitivity with the lowest false-positive results of the studied marker) to differentiate between the two groups under study. If the area under the curve is > 0.5, the variable is able to differentiate between the two groups; the closer this area to 1, the better its differentiating capacity. The best cutoff value of serum AECAs was 254 pg/mL, with the area under the curve being 0.64, indicating that plasma AECA was a good differentiating marker between patients and controls at this cutoff value.
Results
The general characteristics of the study participants and the results of the AECA levels are depicted in Table 1 . Patients exhibited significantly higher serum AECA levels [n ¼ 55, 306.4 ± 45.6 pg/mL (mean ± SEM)] ( p ¼ 0.05, Fig. 1 ) than did normal controls [n ¼ 25, 209.6 ± 24.6 pg/mL (mean ± SEM)]. Increased serum AECA levels were observed in 63% (41/55) of autistic children.
There was a significant difference between normal controls and patients with severe autism (autism diagnoses made on the bases of CARS scores of >40) [n ¼ 20, 369.6 ± 65.6 pg/mL (mean ± SEM)] ( p ¼ 0.03). However, there was no significant difference between the serum AECA levels of children with mild to moderate autism and those with severe autism ( p ¼ 0.16; Fig. 2 ).
There was a positive correlation between disease severity and the CARS score, which represents stereotyped patterns of behavior in children with autism (r 2 ¼ 0.27, p ¼ 0.05; Fig. 3 ). There was no significant difference between the serum AECAs of male and female autistic patients ( p ¼ 0.72). Serum AECA levels of autistic patients exhibited no significant correlations with the ages of autistic children ( p ¼ 0.64).
Discussion
We observed significantly elevated AECA serum levels in autistic children compared with a control group of healthy children. Although caution should be exercised in the interpretation of our data, our results suggest a potential role for AECAs in this neurodevelopmental disorder.
Studies have identified autoantibodies to endothelial cells and nuclei in children with autism, idiopathic mental retardation, and epilepsy, but not in healthy control individuals or those with non-neurologic diseases.
18e22 Several immunologic studies report T-cell dysfunction or abnormal numbers of Tcells in a proportion of autistic patients. 6,21e23 In some studies, autoantibodies are not specific to autism. For example, Todd et al 24 observed antibrain IgG autoantibodies, determined by dot blot analysis, that were nonspecific and present in sera from both normal individuals and depressed patients. Cockwell et al 25 suggested that endothelial cell activation is defined as "quantitative changes" in the expression levels of specific gene products (i.e., proteins), which in turn endow endothelial cells with new functional capacities. Endothelial cell antigens can be constitutively expressed and/or modulated by either cytokines or cryptic means. In addition, antigen determinants for AECAs may also include molecules that adhere to the endothelium. An alternative mechanism by which AECAs could act as a trigger in the pathogenesis of some diseases may involve complement cytotoxicity and/or antibody-dependent cellular cytotoxicity.
26e29
In this study, we measured high mean AECAs in the sera of children with autism compared with healthy controls. Some investigators have reported that endothelial cell activation can be induced by AECAs. Phenotypic changes in the endothelium can be due, in part, to the induction of interleukin (IL)-1 synthesis or other mediators (i.e., IL-1, IL-2, IL-4, IL-6, IL-8, and Macrophage Inflammatory Proteins (MIP)-1). 30 There may be a variety of autoantibodies in individuals with autism. The presence of these autoantibodies may be a secondary marker of disease rather than directly pathogenic. To our knowledge, no one has looked prospectively at autoantibodies in a large cohort of children. Irrespective of whether these autoantibodies are of direct etiological relevance, the presence of a marker of disease in ASDs may be important to help determine the time of onset of these devastating disorders. Other autoimmune diseases have both specific and nonspecific autoantibodies.
The chief caveats of our report are the small sample size and its cross-sectional design. We were only able to observe associations, not predictions or causation. Another limitation of our report is that adaptive behavior was not assessed in the control individuals. Therefore, whether levels of AECA factors may be associated with behavioral features in healthy individuals remains to be established. These caveats notwithstanding, we have demonstrated an alteration of the endothelial cell environment in autism characterized by a clear imbalance of important AECAs.
The knowledge resulting from autoimmunity research has direct clinical relevance to the overall health and recovery of autistic children. Our findings provide preliminary, direct evidence of altered AECAs in patients with ASD, which may contribute to the early pathogenesis of ASD, offer valuable biomarkers, point to novel therapeutic development for autism, and offer a novel approach to immunotherapy with the use of natural immunomodulators.
